$BGNE with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $BGNE after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.29 USD
−647.42 M USD
3.83 B USD
1.04 B
About BEIGENE LTD
Sector
Industry
CEO
John V. Oyler
Website
Headquarters
Basel
Founded
2010
ISIN
CH1391448177
FIGI
BBG00YJV1CB6
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 80%.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 100%.
#6160 pull-back and hits support line $213.6 Hi Everybody
#6160 pull-back and hits support line $213.6, expects to test the BLUE LINES, and stops if closes below the RED line.
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA BGNE: BeiGene, Ltd.
2021-07-29 20:00:00
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BGNE short above 260$, target price 161$, about Mar 9, 2021.BGNE short above 260$, target price 161$, about Mar 9, 2021.
Similar pattern of Aug 8, 2018.
Wait BGNE price reached 161$, start building long position.
It's not a good idea holding BGNE under 270$~260$
Long stop-Loss price : 259$
Short stop-loss price : 284$
BGNE: Long strategy after gap overlapWe will trade long in the range $140 - 150 amid to gap overlap. Target will be $190 / 200. (+30% potentially)
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of BEIGF is 15.95 USD — it has decreased by −16.10% in the past 24 hours. Watch BeOne Medicines Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange BeOne Medicines Ltd. stocks are traded under the ticker BEIGF.
We've gathered analysts' opinions on BeOne Medicines Ltd. future price: according to them, BEIGF price has a max estimate of 37.61 USD and a min estimate of 19.91 USD. Watch BEIGF chart and read a more detailed BeOne Medicines Ltd. stock forecast: see what analysts think of BeOne Medicines Ltd. and suggest that you do with its stocks.
BEIGF reached its all-time high on Mar 31, 2025 with the price of 20.61 USD, and its all-time low was 11.00 USD and was reached on Apr 12, 2024. View more price dynamics on BEIGF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BEIGF stock is 19.18% volatile and has beta coefficient of 0.77. Track BeOne Medicines Ltd. stock price on the chart and check out the list of the most volatile stocks — is BeOne Medicines Ltd. there?
Today BeOne Medicines Ltd. has the market capitalization of 32.42 B, it has decreased by −18.54% over the last week.
Yes, you can track BeOne Medicines Ltd. financials in yearly and quarterly reports right on TradingView.
BeOne Medicines Ltd. is going to release the next earnings report on Aug 22, 2025. Keep track of upcoming events with our Earnings Calendar.
BeOne Medicines Ltd. revenue for the last quarter amounts to 1.11 B USD, despite the estimated figure of 1.13 B USD. In the next quarter, revenue is expected to reach 1.22 B USD.
BEIGF net income for the last quarter is 1.27 M USD, while the quarter before that showed −151.95 M USD of net income which accounts for 100.84% change. Track more BeOne Medicines Ltd. financial stats to get the full picture.
No, BEIGF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 14, 2025, the company has 11 K employees. See our rating of the largest employees — is BeOne Medicines Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BeOne Medicines Ltd. EBITDA is −116.94 M USD, and current EBITDA margin is −10.40%. See more stats in BeOne Medicines Ltd. financial statements.
Like other stocks, BEIGF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BeOne Medicines Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BeOne Medicines Ltd. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BeOne Medicines Ltd. stock shows the neutral signal. See more of BeOne Medicines Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.